THROUGHOUT 2023, HARM REDUCTION THERAPEUTICS (HRT) CONTINUED ITS WORK AS AN INDEPENDENT NONPROFIT FOCUSED EXCLUSIVELY ON SAVING LIVES THAT WOULD OTHERWISE BE LOST TO OPIOID OVERDOSE BY MAKING ITS NALOXONE PRODUCT - RIVIVE (NALOXONE HCL NASAL SPRAY 3MG) - AVAILABLE OVER-THE-COUNTER FREE OF CHARGE OR AT THE LOWEST POSSIBLE COST. RIVIVE USES AN EASY-TO-USE STANDARD UNIT DOSE SYSTEM THAT CAN BE USED IN AN EMERGENCY TO REVERSE THE LIFE-THREATENING EFFECTS OF KNOWN OR SUSPECTED OPIOID OVERDOSE. EACH RIVIVE NASAL SPRAY DEVICE CONTAINS ONE DOSE OF NALOXONE. IT IS EXCLUSIVELY AVAILABLE IN TWIN PACKS CONTAINING TWO SINGLE- DOSE DEVICES. IT IS SAFE TO KEEP ADMINISTERING RIVIVE EVERY TWO TO THREE MINUTES UNTIL THE PERSON WAKES UP FROM THEIR OPIOID OVERDOSE. 2023 WAS A SEMINAL YEAR FOR RIVIVE, AND HOPEFULLY WILL MARK A TURNING POINT IN THE ONGOING OPIOID CRISIS. IN LATE JULY 2023, THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVED OVER-THE-COUNTER RIVIVE FOR THE EMERGENCY TREATMENT OF OPIOID OVERDOSE. THIS CRITICAL MILESTONE WILL HELP PREVENT OPIOID OVERDOSE DEATHS BY MAKING FREE OR LOW-COST OVER-THE-COUNTER (OTC) NALOXONE NASAL SPRAY AVAILABLE TO EVERYONE IN THE UNITED STATES. NO COMPANY, ENTITY, OR INDIVIDUAL WILL PROFIT FROM SALES OF RIVIVE. SINCE 2017, MORE THAN 290,000 PEOPLE ACROSS THE U.S. HAVE DIED OF AN OPIOID OVERDOSE. HRT STANDS BEHIND THE PRINCIPLE ARTICULATED BY THE WHITE HOUSE AND OFFICE OF NATIONAL DRUG CONTROL POLICY DIRECTOR DR. RAHUL GUPTA THAT "NO ONE WHO NEEDS OVERDOSE REVERSAL MEDICATIONS SHOULD LACK ACCESS BECAUSE OF COSTS OR AVAILABILITY." HRT BEGAN MANUFACTURING RIVIVE AT-RISK TO MINIMIZE THE TYPICAL LAG BETWEEN FDA APPROVAL AND LAUNCH OF A NEW PRODUCT. AS A RESULT, HRT ANTICIPATED THAT RIVIVE WOULD BE AVAILABLE IN EARLY 2024 PRIMARILY TO U.S. HARM REDUCTION ORGANIZATIONS AND STATE GOVERNMENTS FOR COSTS LOWER THAN OTHER OPIOID ANTAGONIST NASAL SPRAYS. IN DECEMBER 2023, HRT SHIPPED ITS FIRST ORDER RIVIVE TO THE NONPROFIT REMEDY ALLIANCE/FOR THE PEOPLE (HTTPS://REMEDYALLIANCEFTP.ORG), MARKING A CRUCIAL STEP IN HRT'S SINGULAR MISSION OF PREVENTING OPIOID OVERDOSE DEATHS BY MAKING FREE-OF-CHARGE OR LOW-COST OVER-THE-COUNTER NALOXONE AVAILABLE TO EVERYONE IN THE UNITED STATES, PRIMARILY THROUGH NONPROFIT COMMUNITY HARM REDUCTION ORGANIZATIONS AS WELL AS STATE AND LOCAL GOVERNMENTS. LASTLY, BECAUSE OF HRT'S WORK DEVELOPING AND OBTAINING FDA APPROVAL FOR RIVIVE, MANUFACTURERS OF OTHER NALOXONE PRODUCTS FINALLY APPLIED FOR FDA OTC APPROVAL OF THEIR PRODUCTS , AFTER YEARS OF DELAY PRIOR TO OUR WORK, MEANING THAT HRT HELPED TO FUNDAMENTALLY IMPROVE THE ACCESSIBILITY OF LIFE-SAVING NALOXONE PRODUCTS ACROSS THE U.S.
Application Information
Accepts Unsolicited ProposalsNo — Preselected Only